چكيده به لاتين
The pharmaceutical industry is considered as a global industry and given the impact of human life, can endanger human life by creating the problem of access to pharmaceutical products in terms of the volume of production and distribution, and it is very important in this regards. Nowadays the globalization of commerce and the advent of international companies attract more attention to global supply chain. On the other hand, the rapid changing global status has significant effects for the pharmaceutical supply chain and its application is of great importance. It is also vital for a pharmaceutical company to stay in the competitive market and move towards a sustainable business, which is vital in the development and investment of new products as far as possible. Based on mentioned points, this thesis aims to sets all aspects of the global pharmaceutical supply chain issue, for the first time and creates an integrated model that coordinates the research and development, production and distribution sectors for generic and innovative drugs in pharmaceutical supply chain. For this purpose, an integrated model with maximizing “Expected Net Present value” (profit), minimizing maximum unsatisfied demand and maximizing production of innovative drugs for Hakim pharmaceutical company’s global supply chain is proposed. Then, to cope with the parameters tainted with high degree of uncertainty, a new effectual credibility-based robust possibilistic programming model is elaborated. The proposed robust possibilistic programming model is able to appropriately adjust the degree of feasibility and optimality robustness of output decisions against business-as-usual uncertainty. Also the proposed robust optimization model can be appropriately applied in the cases in which reliable and sufficient historical data is not available for imprecise parameters (i.e., most of the real-life problems). To show the usefulness and effectiveness of the proposed model numerical and comparative experiments are provided. Finally, the numerical results endorse the validity and practicability of the rendered model as well as presenting the efficiency and felicity of the developed approach. Given the outputs of the model, determination of the exact amount of fines in the programming model is very significant. According to necessity of planning the R&D and production simultaneously, data and charts show that an integrated R&D and production of generic and innovative pharmaceuticals compare to the non-integrated model has improved 20/34%. In this regard, this thesis used the R&D and production planning concurrently.
Keywords: Integrated Research and Development, Production and distribution planning,
R&D in Pharmaceutical Industry, Global pharmaceutical supply chain, Robust possibilistic programming
